Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.
The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-gamma isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-gamma agonist, in the management of type 2 diabetes mellitus. In this review, we discuss the pathogenic role of PPAR-gamma in experimental models of kidney disease, clinical trials of thiazolidinediones in diabetic and non-diabetic kidney disease, recent safety concerns surrounding PPAR-gamma agonists and reflect on their potential use in 'orphan' kidney diseases.
Mao
Zhiguo
Z
Kidney Genetics Group, Academic Nephrology Unit, Research Center, University of Sheffield Medical School, Sheffield, UK.
Ong
Albert C M
AC
D005544:Forecasting; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D007674:Kidney Diseases / Q000188:drug therapy* / Q000378:metabolism*; D009398:Nephrology / Q000639:trends; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism*; D045162:Thiazolidinediones / Q000008:administration & dosage*
D047495:PPAR gamma; D045162:Thiazolidinediones